The identification of L7N/mL7N as highly effective peptides in modulating the PD-1/PD-L1 immune checkpoint in vitro and curbing tumor growth in vivo underscores the importance of combining unbiased functional screening with rational peptide design. The gene discussed is CD274; the disease is neoplasm.